Bausch Health Companies Inc.

BHC

CA0717341071

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2026-03-05 EST			5-day change	1st Jan Change
5.570 ^USD	-1.07%		-7.78%	-19.86%

02-23	Bausch Health Launches New Skin Laser in Canada	MT
02-19	TSX hits another record high as commodity-linked stocks climb	RE

Bausch Health Companies Insider Bought Shares Worth $14,700,257, According to a Recent SEC Filing

Published on 06/13/2025 at 03:17 am EDT

MT Newswires

Latest news about Bausch Health Companies Inc.

02-23	Bausch Health Launches New Skin Laser in Canada	MT
02-19	TSX hits another record high as commodity-linked stocks climb	RE
02-19	Bausch Health Companies Inc. Announces 25 Years of Arestin®? (Minocycline Hcl) Microspheres	CI
02-18	Bausch Health Companies Inc., Q4 2025 Earnings Call, Feb 18, 2026
02-18	Bausch Health Swings to Q4 Loss, Revenue Rises; Shares Drop After Hours	MT
02-18	Earnings Flash (BHC) Bausch Health Posts Q4 Loss $0.30 per Share, vs. FactSet Est of $0.58 EPS	MT
02-18	Earnings Flash (BHC) Bausch Health Companies Posts Q4 Revenue $2.8B, vs. FactSet Est of $2.74B	MT
02-18	Bausch Health Down 8.6% After hours as Q4 Adjusted Earnings Narrow, But Revenue up	MT
02-18	BHC Brief: Q4 Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP) of US$1.05B	MT
02-18	BHC Brief: Q4 GAAP Net Loss Attributable US$112M	MT
02-18	Bausch Health Companies Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-18	BHC Brief: Q4 Consolidated Revenues of US$2.80 billion	MT
02-18	Bausch Health Companies Inc. Provides Earnings Guidance for the Full Year 2026	CI
02-18	Bausch Health Companies Inc. Announces Impairment Results for the Fourth Quarter Ended December 31, 2025	CI
02-13	Diary - Canada corporate earnings week ahead	RE

Chart Bausch Health Companies Inc.

Duration

Period

BHC: Dynamic Chart

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Employees

20,300

Sector

Pharmaceuticals

More about the company